2. Is Bafna Pharmaceuticals Ltd undervalued or overvalued?
The key valuation ratios of Bafna Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Bafna Pharmaceuticals Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Bafna Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
10 Year X-Ray of Bafna Pharma:
Analysis of Financial Track Record
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Bafna Pharmaceuticals Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
Value Creation Index Colour Code Guide
ⓘ
Mar'14
Mar'15
Mar'16
Mar'17
Mar'18
Mar'19
Mar'20
Mar'21
Mar'22
Mar'23
TTM
ROCE % ⓘ
6.9%
11.1%
-2.6%
-8.1%
-30.7%
-23.7%
-3.2%
9.8%
7.7%
13.6%
-
Value Creation Index ⓘ
-0.5
-0.2
-1.2
-1.6
-3.2
-2.7
NA
-0.3
-0.5
0.0
-
Growth Parameters ⓘ
Growth Parameters Colour Code Guide
ⓘ
Sales ⓘ
178
143
85.3
65
47.2
43.6
42.5
71.2
85.1
115
153
Sales YoY Gr.
-
-19.7%
-40.1%
-23.9%
-27.4%
-7.5%
-2.7%
67.7%
19.6%
35.5%
-
Adj EPS ⓘ
1.5
4.4
-6.6
-10.1
-15.9
-8.3
-8.4
2.4
2.1
4.3
4.8
YoY Gr.
-
192%
-249.8%
NA
NA
NA
NA
NA
-10.6%
102.4%
-
BVPS (₹) ⓘ
32.6
38.4
31.5
22
17.1
8.8
-18.6
24
26.2
31.1
33.6
Adj Net Profit ⓘ
2.8
8.2
-12.2
-18.8
-37.7
-19.7
-2
5.6
5
10.1
11
Cash Flow from Ops. ⓘ
0.8
9.5
-3
19.8
-7.1
-1.1
-34.3
-13.6
9.7
5
-
Debt/CF from Ops. ⓘ
129.1
6.7
-27.1
4.2
-6.6
-42.2
-0.1
-1
1.1
4.6
-
CAGR ⓘ
CAGR Colour Code Guide
ⓘ
9 Years
5 Years
3 Years
1 Years
Sales ⓘ
-4.7%
19.6%
39.5%
35.5%
Adj EPS ⓘ
12.3%
NA
NA
102.4%
BVPSⓘ
-0.6%
12.6%
NA
18.6%
Share Price
13.2%
57.4%
-14%
2.2%
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide
ⓘ
Mar'14
Mar'15
Mar'16
Mar'17
Mar'18
Mar'19
Mar'20
Mar'21
Mar'22
Mar'23
TTM
Return on Equity % ⓘ
4.1
11.6
-18.7
-35.9
-88.2
-64.4
-5.5
10.3
8.4
14.9
14.7
Op. Profit Mgn % ⓘ
13.2
18
3.8
-8
-74.4
-29.8
3
14.5
14
13.6
10.3
Net Profit Mgn % ⓘ
1.6
5.7
-14.4
-28.9
-80
-45.2
-4.7
7.8
5.8
8.7
7.4
Debt to Equity ⓘ
1.6
0.9
1.4
2
1.2
2.2
-0.7
0.2
0.2
0.3
-
Working Cap Days ⓘ
304
336
490
603
721
682
459
193
212
208
97
Cash Conv. Cycle ⓘ
104
152
247
290
236
31
3
40
74
81
48
Recent Performance Summary
Return on Equity has increased versus last 3 years average to 14.70%
Sales growth is growing at healthy rate in last 3 years 39.52%
Company share prices are keep on changing according to the market conditions. The closing price of Bafna Pharma on 25-Apr-2024 16:01 is ₹86.94.
What is the market cap of Bafna Pharma?
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 25-Apr-2024 16:01 the market cap of Bafna Pharma stood at ₹205.7.
What is the P/E ratio of Bafna Pharma?
The latest P/E ratio of Bafna Pharma as of 25-Apr-2024 16:01 is 18.26.
What is the P/B ratio of Bafna Pharma?
The latest P/B ratio of Bafna Pharma as of 25-Apr-2024 16:01 is 2.59.
What is the 52-week high and low of Bafna Pharma?
The 52-week high of Bafna Pharma is ₹125.5 and the 52-week low is ₹76.50.
What is the TTM revenue of Bafna Pharma?
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bafna Pharma is ₹153.3 ( Cr.) .
About Bafna Pharmaceuticals Ltd
Bafna Pharmaceuticals was incepted by Bafna Mahaveer Chand in 1981 as a proprietary concern. It was converted into a public limited company on 28th march 1995. The company started its own manufacturing unit in October 1984.
Bafna Pharmaceuticals started its production with tablets facility and subsequently added capsule and oral syrup facilities respectively. BAFNA always focused on institutional and generic supply to keep its production line busy. It also concentrated on registering its products in the international market.
The present manufacturing facilities of BAFNA is set up at Chennai. The facility for producing Betalactam products was constructed in the year 2001 in a separate block.
It acquired 2.65 acres of factory land in Grantylon village, near Chennai to expand its operations to regulated market like US and UK and also to manufacture its own products.
The company’s vision is to become a leading professionally run global pharma company setting standards across the pharma value chain.
ProductRange:
Antibacterials
Antipyretics
Antconvulsants
Anxiolytics
Pain management
Anthelmintics
Antifungal
Appetite stimulants
Antidiarrhoeals
Antiemetics
Hypnotics
Antacids and antiulcerants
Vitamin and dietery preparation
Cough and cold preparations
Antiasthmatics
Calcium preparations
Antihypertensives
Antidiabetics
Achievements/ Awards:
BAFNA was awarded the WHO GMP in the year 1995.
Bagged the ‘Best Supplier Award’ from the State Pharmaceutical Corporation of Sri Lanka on 30th July 2005.
Accorded the status of an ‘Export House’ in recognition of its excellent export performance.
Received Medicines and Health Care Products Regulatory Agency (MHRA) approval for its Grantlyon facility meant for exports to the UK markets. Bafna was the 35th company in the Indian pharmaceuticals industry (IPI) to receive MHRA approval.
2009 ISO 9001: 2000 Certificate of Registration for Manufacture and Export of Pharmaceutical products
MHRA Certificate of GMP Compliances of Manufacturer from Medicines and Healthcare products Regulatory Agency, U.K.
2010 Bafna Pharmaceuticals have been awarded the Gold Quality Excellence Award 2009
Bafna Pharmaceuticals have inaugurated its Formulation Research & Development unit (Formulation Facility) in Chennai
2011 Bafna Pharmaceuticals has received Indian Drug Manufacturer's Association (IDMA) Quality Excellence Award 2010 - Silver Award under the category of Formulations Units
Bafna Pharmaceuticals has received Udyog Rattan Award and Excellence Award from the Institute of Economic Studies Delhi.
Company quality is determined using minimum hurdle rate for return on capital employed and free cash flows for last 10 years.
Companies with smaller size have higher hurdle rate.
High quality stocks are important for long term investment.
Value
Valuation is computed by comparing relevant price multiples versus industry and its own history.
One unique and very important modification is our adjustment for company's financials for cyclicality and normalized profitability.
or based on whether current ratio is lower or higher than median values. See graph for better assessment.
Valuation is important for long term investment.
Actual valuation done by our Equity Analysts may differ from the Free DeciZen maker valuation. Subscribe to our premium products for more information on actual valuation
Price
Price rating is given based on stock price strength using moving averages and relative strength on shorter timeframe.
Short term time frame has little to no significance for long term investing but it can help in deciding how fast or how slow one can add a stock top your portfolio.
Only after a stock satisfies Quality and Value parameters, use price trend to build a position. Add slowly if price trend is Red or Orange. Add quickly if price trend is Green.
You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
Detailed Chart
Create stable, long-term investment portfolio with strong, consistent stocks.
MoneyWorks4Me method for rating and ranking mutual funds for SIP
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and
ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the
various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Performance Consistency: This is measure based on whether the fund has beaten the benchmark index consistently. For
this we compare the 3-year rolling returns of the fund with the benchmark for a minimum of 5 years and preferable 10
years. The period of rolling is one month and holding period is 3 years. Fund are color-coded Green on Performance when
the fund beats the benchmark more than 90% of the time. It is Orange if it beats 80% to 90% of the time and Red if less
than 80%. Funds with less than 5 year data are color-coded Grey.
Quality of Portfolio Holding: Moneyworks4Me has color-coded stocks as Green, Orange and Red based on whether the
company's performance has generated a ROCE above a threshold level (cost of capital) over 10 years (minimum 6 years) and
generated positive Free Cash Flow. For Banks it checks whether ROE is greater than 15% and sales has grown over previous
year. Stocks that perform consistently on these combined metrics are color-coded Green (min score 14 out of 20), Orange
(between 8 and 14) and Red (less than 8 out of 20).
Fund are color-coded Green provided the portfolio has 70% holding in Green stocks but not more than 20% in Red stocks.
Funds with more than 20% Red stocks in the portfolio are color-coded Red. The rest are Orange funds
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The
ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number
that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Looking to make the most of market corrections and volatility?
Did you know that market corrections can actually present great opportunities to buy high-quality stocks at discounted prices? By taking advantage of these times of volatility, you can position your portfolio for long-term growth.
At MoneyWorks4me Portfolio Advisory, we specialize in helping investors navigate market fluctuations and build a strong, diversified portfolio. With our collaborative approach, you can maintain control over your investments while benefiting from our expertise and guidance.
If you're interested in learning more and with a minimum portfolio size of 25 L+, we can help you manage your portfolio, no matter the size. let's connect and discuss how we can work together. And as a bonus, we're offering a FREE Portfolio Review using our "Portfolio Manager" tool during our conversation.
So why wait?
Let's get started today and take your portfolio to the next level!
Best Buy Stocks
Do you want to Invest in Undervalued Handpicked stocks and earn high Returns?
Why Buy Quality Stocks
Winning and long lasting portfolio is made of Quality Stocks, but how simple is that?
Important Questions while Buying Stocks
As an Investor most important decision making questions are?
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
You can make an informed decision based on:
Q : Quality :- Q Very Good
Q Somewhat Good
Q Not Good
V : Valuation:- V+UnderValued (UV) V Somewhat UV
V Fair Value
V Somewhat OV
V+ OverValued (OV)
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Make an informed decision for Funds
You can make an informed decision based on:
P : Performance (%)* 14 Very Good
14 Somewhat Good
12 Not Good
Less than 5 year data
Q : Quality of Holding Q Very Good
Q Somewhat Good
Q Not Good
*Color code for outperformance consistency
*Number is average 3 year rolling returns
Want to invest successfully in stocks?
How the heck do you select a solution that ensures it?
Does it get you focused on meeting your financial goals?
Does it get you focused on meeting your financial goals?
Investing is to means to funding your goals. Your solution must help you get clarity of your goals and how you should invest to reach them. Does your solution include Financial Planning?
Download APP
